Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
तुलना करने के लिए मीट्रिक्स | BMND | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBMNDपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | - | −0.6x | −0.6x | |
PEG अनुपात | - | 0.00 | 0.00 | |
क़ीमत/बुक | - | 0.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 3.7x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 47.1% | 48.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 23.4% | 6.8% | अनलॉक करें |